« Back
Home /
GSK2033

GSK2033

Item no.	HY-108688-5mg
Manufacturer	MedChem Express
CASRN	1221277-90-2
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Neuroscience Metabolism Cholesterol & Lipid Metabolism Molecular Targets for Neuroscience Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.22
Formula	C29H28F3NO5S2
Citations	[1]Zuercher WJ, et al. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6.<br>[2]Griffett K, et al. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochem Biophys Res Commun. 2016 Oct 21;479(3):424-428.
Smiles	O=S(C1=C(C)C=C(C)C=C1C)(N(CC2=CC=C(C3=CC=CC(S(=O)(C)=O)=C3)C=C2)CC4=CC=C(C(F)(F)F)O4)=O
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1221277-90-2
Available
Product Description	GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Metabolism-sugar/lipid metabolism
MolecularWeight	591.66
Clinical_Information	No Development Reported
Manufacturers Research Area	Metabolic Disease
Solubility	DMSO : 30 mg/mL (ultrasonic; warming)
Manufacturers Target	LXR
Pathway	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-108688-5mg-safety-datasheet.pdf